Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | TLR2 | O60603 | 3/20 | 0.46 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31758332 | 1.00 | KMT2A (0.58) | KMT2ATLR2TLR1MDM2MAPT | |
| SCHEMBL28629485 | 1.00 | KMT2A (0.58) | KMT2ATLR2TLR1MDM2MAPT | |
| Hydrochloric Acid SCHEMBL29380070 | 0.99 | KMT2A (0.57) | KMT2ATLR2TLR1MDM2MAPT | |
| SCHEMBL4906458 | 0.92 | KMT2A (0.54) | KMT2ATLR2TLR1MDM2MAPT | |
| Hydrochloric Acid SCHEMBL29902249 | 0.92 | KMT2A (0.52) | KMT2ATLR2TLR1MDM2EPHX2 | |
| SCHEMBL30887302 | 0.89 | KMT2A (0.63) | KMT2ATLR2EPHX2DPP8DPP7 | |
| SCHEMBL14682729 | 0.89 | KMT2A (0.63) | KMT2ATLR2EPHX2DPP8DPP7 | |
| SCHEMBL15160784 | 0.89 | KMT2A (0.63) | KMT2ATLR2EPHX2DPP8DPP7 | |
| SCHEMBL12972620 | 0.89 | KMT2A (0.63) | KMT2ATLR2EPHX2DPP8DPP7 | |
| SCHEMBL6669959 | 0.89 | KMT2A (0.53) | KMT2ATLR2TLR1MDM2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4663652-A1 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | Novartis AG (CH) | 2025-12-17 | — | — | EP | disclosed |
| WO-2025199636-A1 | TARGETED RADIOLIGAND COMPOUNDS AND USES THEREOF | MCMASTER UNIVERSITY (CA) | 2025-10-02 | — | — | WO | disclosed |
| EP-4247833-B1 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | NOVARTIS AG (CH) | 2025-09-24 | — | — | EP | disclosed |
| EP-4247798-B1 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | NOVARTIS AG (CH) | 2025-08-27 | — | — | EP | disclosed |
| US-20250213705-A1 | PSMA TARGETING LIGANDS AND METHODS OF USE | BRIGHT PEAK THERAPEUTICS AG (CH) | 2025-07-03 | — | — | US | disclosed |
| WO-2025088147-A1 | THERANOSTIC PSMA-TARGETING LIGANDS FOR THE DIAGNOSIS AND TREATMENT OF PSMA-EXPRESSING CANCERS AND THEIR SOLID PHASE SYNTHESIS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025041103-A1 | PSMA TARGETING LIGANDS AND METHODS OF USE | BRIGHT PEAK THERAPEUTICS AG (CH) | 2025-02-27 | — | — | WO | disclosed |
| US-12234242-B2 | Radiopharmaceuticals, radioimaging agents, and uses thereof | Clarity Pharmaceuticals Ltd (AU) | 2025-02-25 | — | — | US | disclosed |
| US-20240025866-A1 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | NOVARTIS AG (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20240018099-A1 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | NOVARTIS AG (CH) | 2024-01-18 | — | — | US | disclosed |
| EP-4247833-A1 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | Novartis AG (CH) | 2023-09-27 | — | — | EP | disclosed |
| EP-4247785-A1 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | Novartis AG (CH) | 2023-09-27 | — | — | EP | disclosed |
| EP-4209495-A1 | RADIOPHARMACEUTICALS AND PROCESSES FOR THEIR PREPARATION | Clarity Pharmaceuticals Ltd (AU) | 2023-07-12 | — | — | EP | disclosed |
| EP-3634965-B1 | RADIOPHARMACEUTICALS, RADIOIMAGING AGENTS, AND USES THEREOF | Clarity Pharmaceuticals Ltd (AU) | 2023-02-22 | — | — | EP | disclosed |
| US-20220211883-A1 | FAP-ACTIVATED RADIOTHERANOSTICS AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2022-07-07 | — | — | US | disclosed |
| WO-2022133288-A1 | FAP-ACTIVATED RADIOTHERANOSTICS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022106636-A1 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | NOVARTIS AG (CH) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022106633-A1 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | NOVARTIS AG (CH) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022106629-A1 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | NOVARTIS AG (CH) | 2022-05-27 | — | — | WO | disclosed |
| CN-110272539-B | Ligand conjugate and probe for binding PMSA (PMSA), and preparation method and application thereof | 广东工业大学 | 2021-09-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213705-A1 | PSMA TARGETING LIGANDS AND METHODS OF USE | FOLH1, KLK3, PSMA2 | KMT2A 2923/4885TLR2 4471/4885TLR1 4680/4885 |
| US-20220211883-A1 | FAP-ACTIVATED RADIOTHERANOSTICS AND USES RELATED THERETO | FAP, FIBP, FGFR1 | KMT2A 3435/4885TLR2 3747/4885TLR1 3578/4885 |
| US-20240025866-A1 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | FOLH1, KLK3, BPHL | KMT2A 1041/4885TLR2 3544/4885TLR1 3724/4885 |
| US-20240018099-A1 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | FOLH1, KLK3, BPHL | KMT2A 1041/4885TLR2 3544/4885TLR1 3724/4885 |
| US-12234242-B2 | Radiopharmaceuticals, radioimaging agents, and uses thereof | SLC30A5, SLC40A1, FOLH1 | KMT2A 1151/4885TLR2 4107/4885TLR1 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.